查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598699

結核病診斷市場：按測試類型、類型和最終用戶 - 2025-2030 年全球預測

Tuberculosis Diagnostics Market by Test Type (Drug-susceptibility Testing, Laboratory Methods, Mantoux Test), Type (Point-of-Care Technologies, Rapid Test), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年結核病診斷市值為30.1億美元，預計到2024年將達到31.7億美元，複合年成長率為5.48%，到2030年將達到43.8億美元。

結核病診斷的範圍包括旨在識別結核分枝病菌感染的各種測試和程序。這包括痰液顯微鏡檢查、培養等傳統方法和核酸增幅檢查(NAAT) 等新型分子診斷方法。結核病是感染疾病導致死亡的主要原因，全球的結核病負擔強調了有效結核病診斷的必要性。其應用範圍廣泛，從早期診斷和治療反應監測到藥物敏感性測試。最終用途包括醫院、診斷實驗室和研究機構，強調臨床和公共衛生觀點。

主要市場統計
基準年[2023] 30.1億美元
預測年份 [2024] 31.7億美元
預測年份 [2030] 43.8億美元
複合年成長率（%） 5.48%

根據市場洞察，技術進步、結核病患者病率上升以及醫療基礎設施改善是成長的主要動力。特別是，與傳統方法相比，更高的準確性和更快的結果促進了向分子診斷的快速過渡。潛在的商機存在於結核病患者病率較高但診斷設施有限的新興國家。在那裡，我們可以透過與政府健康和衛生計劃的合作來擴大市場。然而，主要挑戰包括先進診斷的高昂成本、結核病細菌類型的準確性差異以及低收入地區的認知較低。

創新領域包括開發具有成本效益的照護現場診斷工具，以提供快速可靠的結果。這些有可能徹底改變結核病診斷，特別是在農村和資源有限的環境中。此外，研究檢測抗藥性結核分枝桿菌的方法可能會在對抗多重抗藥性結核病的鬥爭中取得重大突破。

由於國內外參與者眾多，該市場呈現分散性，企業可以透過投資產品差異化和策略聯盟來取得成功。與非政府組織和公共衛生計畫的合作可以增強市場滲透和推廣工作。識別這些促進因素並透過有針對性的研究和策略規劃解決限制將導致結核病診斷市場的持續成長。

市場動態：揭示快速發展的結核病診斷市場的關鍵市場洞察

結核病診斷藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球結核病負擔日益增加以及早期診斷的必要性
    • 研發投入增加，診斷產品集中化
    • 政府支持措施和新興市場意識的提高
  • 市場限制因素
    • 結核病診斷藥物的高成本
    • 有限的兌換選項
  • 市場機會
    • 加強政府意識計劃
    • 診斷方法的進展
  • 市場挑戰
    • 新興市場的覆蓋率低或沒有保險

波特五力策略工具引領結核病診斷市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對結核病診斷藥物市場的影響

外部宏觀環境因素在塑造結核病診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解結核病診斷藥物市場的競爭狀況

對結核病診斷市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 結核病診斷市場中的定位矩陣供應商績效評估

FPNV定位矩陣是評估結核病診斷市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，描繪結核病診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，結核病診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球結核病負擔不斷增加，增加了早期診斷的需求。
      • 增加研發投資和研發中的密集診斷產品
      • 政府的支持努力和新興市場意識的提高
    • 抑制因素
      • 結核病診斷藥物的高成本
      • 退款選項有限
    • 機會
      • 加強政府意識計劃
      • 診斷程序的進展
    • 任務
      • 新興市場的保險覆蓋率低或沒有
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章結核病診斷市場：依測試類型

  • 藥敏試驗
  • 實驗方法
  • 曼圖測試
  • 核酸檢測
  • 射線照相

第7章結核病診斷藥物市場：依類型

  • 照護現場技術
  • 快速測試

第8章結核病診斷市場：依最終用戶分類

  • 診斷研究室
  • 醫院/診所

第9章北美和南美結核診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太結核病診斷藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章：歐洲、中東和非洲的結核病診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Becton, Dickinson, and Company
  • bioMerieux SA
  • Bruker Corporation
  • Cepheid
  • Elisabeth Pharmacon, spol. s ro
  • ELITech Group
  • F. Hoffmann-La Roche AG
  • Hologic Corporation
  • OSANG HEALTHCARE CO., LTD
  • PerkinElmer, Inc.
  • Siemens AG
  • Thermo Fisher Scientific, Inc.
  • Turklab AS
Product Code: MRR-03252A5F9274

The Tuberculosis Diagnostics Market was valued at USD 3.01 billion in 2023, expected to reach USD 3.17 billion in 2024, and is projected to grow at a CAGR of 5.48%, to USD 4.38 billion by 2030.

The scope of Tuberculosis (TB) Diagnostics encompasses various tests and procedures aimed at identifying Mycobacterium tuberculosis infection. This includes traditional methods like sputum microscopy, culture tests, and newer molecular diagnostics such as nucleic acid amplification tests (NAATs). The necessity for effective TB diagnostics is underscored by the global burden of tuberculosis, which remains a leading cause of death from an infectious disease. Applications stretch from initial diagnosis and monitoring of treatment response to drug susceptibility testing. End-use sectors include hospitals, diagnostic laboratories, and research institutions, emphasizing both clinical and public health perspectives.

KEY MARKET STATISTICS
Base Year [2023] USD 3.01 billion
Estimated Year [2024] USD 3.17 billion
Forecast Year [2030] USD 4.38 billion
CAGR (%) 5.48%

Market insights reveal that technological advancements, rising TB prevalence, and improved healthcare infrastructure are primary growth influencers. Particularly, the rapid switch to molecular diagnostics is spurred by their higher accuracy and faster results compared to conventional methods. Potential opportunities lie in emerging economies where TB prevalence is high but diagnostic facilities remain limited. There, partnerships with government health initiatives could expand market reach. However, high costs associated with advanced diagnostics, varied accuracy across different TB strains, and limited awareness in low-income regions pose significant challenges.

Innovation areas ripe for exploration include the development of cost-effective, point-of-care diagnostic tools that offer rapid and reliable results. These could revolutionize TB diagnostics, especially in rural and resource-constrained settings. Moreover, research into drug-resistant TB detection methods could provide essential breakthroughs in combating multi-drug resistant tuberculosis.

As the market predominantly displays a fragmented nature due to numerous local and international players, businesses can succeed by investing in product differentiation and strategic collaborations. Collaboration with NGOs and public health programs can enhance market penetration and outreach efforts. Identifying these drivers and addressing the limitations through targeted research and strategic planning can lead to sustained growth in the tuberculosis diagnostics market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tuberculosis Diagnostics Market

The Tuberculosis Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing burden of tuberculosis globally and need to diagnose at very early stage
    • Increasing R&D investments and intensive diagnostics products in pipelines
    • Supportive government initiatives and rising awareness in the emerging markets
  • Market Restraints
    • High costs associated with tuberculosis diagnostics
    • Limited reimbursement options
  • Market Opportunities
    • Rising number of government awareness programs
    • Advancement in the diagnostics procedures
  • Market Challenges
    • Low coverage or absence of insurance in emerging markets

Porter's Five Forces: A Strategic Tool for Navigating the Tuberculosis Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tuberculosis Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tuberculosis Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tuberculosis Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tuberculosis Diagnostics Market

A detailed market share analysis in the Tuberculosis Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tuberculosis Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tuberculosis Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tuberculosis Diagnostics Market

A strategic analysis of the Tuberculosis Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tuberculosis Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON Laboratories, Inc., Becton, Dickinson, and Company, bioMerieux SA, Bruker Corporation, Cepheid, Elisabeth Pharmacon, spol. s r.o., ELITech Group, F. Hoffmann-La Roche AG, Hologic Corporation, OSANG HEALTHCARE CO., LTD, PerkinElmer, Inc., Siemens AG, Thermo Fisher Scientific, Inc., and Turklab A.S..

Market Segmentation & Coverage

This research report categorizes the Tuberculosis Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Drug-susceptibility Testing, Laboratory Methods, Mantoux Test, Nucleic Acid Testing, and Radiographic Methods.
  • Based on Type, market is studied across Point-of-Care Technologies and Rapid Test.
  • Based on End_User, market is studied across Diagnostics Research Laboratory and Hospital & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing burden of tuberculosis globally and need to diagnose at very early stage
      • 5.1.1.2. Increasing R&D investments and intensive diagnostics products in pipelines
      • 5.1.1.3. Supportive government initiatives and rising awareness in the emerging markets
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with tuberculosis diagnostics
      • 5.1.2.2. Limited reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising number of government awareness programs
      • 5.1.3.2. Advancement in the diagnostics procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Low coverage or absence of insurance in emerging markets
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tuberculosis Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Drug-susceptibility Testing
  • 6.3. Laboratory Methods
  • 6.4. Mantoux Test
  • 6.5. Nucleic Acid Testing
  • 6.6. Radiographic Methods

7. Tuberculosis Diagnostics Market, by Type

  • 7.1. Introduction
  • 7.2. Point-of-Care Technologies
  • 7.3. Rapid Test

8. Tuberculosis Diagnostics Market, by End_User

  • 8.1. Introduction
  • 8.2. Diagnostics Research Laboratory
  • 8.3. Hospital & Clinics

9. Americas Tuberculosis Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tuberculosis Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tuberculosis Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ACON Laboratories, Inc.
  • 3. Becton, Dickinson, and Company
  • 4. bioMerieux SA
  • 5. Bruker Corporation
  • 6. Cepheid
  • 7. Elisabeth Pharmacon, spol. s r.o.
  • 8. ELITech Group
  • 9. F. Hoffmann-La Roche AG
  • 10. Hologic Corporation
  • 11. OSANG HEALTHCARE CO., LTD
  • 12. PerkinElmer, Inc.
  • 13. Siemens AG
  • 14. Thermo Fisher Scientific, Inc.
  • 15. Turklab A.S.

LIST OF FIGURES

  • FIGURE 1. TUBERCULOSIS DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TUBERCULOSIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TUBERCULOSIS DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG-SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LABORATORY METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MANTOUX TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY RADIOGRAPHIC METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS RESEARCH LABORATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 146. TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023